Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 1494 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 
Table of Contents
BRIEF COMMUNICATION
Year : 2013  |  Volume : 17  |  Issue : 5  |  Page : 913-916

Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment


1 Department of Neurology, PGIMER, Chandigarh, India
2 Department of Medicine, Government Medical College and Hospital, Chandigarh, India

Date of Web Publication29-Aug-2013

Correspondence Address:
Yashdeep Gupta
Department of Medicine, Government Medical College and Hospital, Chandigarh - 160 030
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2230-8210.117215

Rights and Permissions
   Abstract 

Glucocorticoid-induced myopathy is the most common type of drug-induced myopathy. Nearly 60% of patients with Cushing's syndrome have muscle weakness. Glucocorticoid-induced muscle atrophy affects mainly fast-twitch glycolytic muscle fibers (type IIb fibers). This brief review will discuss the pathophysiology behind glucocorticoid-induced myopathy, along with diagnostic features and treatment.

Keywords: Glucocorticoid, myopathy, steroid


How to cite this article:
Gupta A, Gupta Y. Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment. Indian J Endocr Metab 2013;17:913-6

How to cite this URL:
Gupta A, Gupta Y. Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment. Indian J Endocr Metab [serial online] 2013 [cited 2020 Apr 2];17:913-6. Available from: http://www.ijem.in/text.asp?2013/17/5/913/117215


   Introduction Top


Glucocorticoid-induced myopathy was first described by Harvey Cushing in 1932 in Cushing's syndrome. [1] He noted that patients with endogenous glucocorticoid excess developed severe proximal muscle wasting and weakness. Around 60% of the patients with Cushing's syndrome develop muscle weakness. [2] With increasing use of glucocorticoids to treat several medical conditions, exogenous glucocorticoids have become the most common cause of drug-induced myopathy. [3] Although any commonly used glucocorticoid can cause myopathy, it is implicated more often with the fluorinated glucocorticoid preparations, such as dexamethasone, triamcinolone, and betamethasone. [4] Improvement in muscle weakness is observed when converted to equivalent anti-inflammatory dose of another steroid. [4]


   Pathophysiology Top


Glucocorticoids alter protein metabolism. They decrease the rate of protein synthesis leading to muscle atrophy, but the main effect is to induce muscle protein catabolism. [3] In experimental data from rat studies, muscle atrophy resulted mainly from increased protein breakdown in adult rats, and depressed protein synthesis in aged animals. [5]

Type of muscle fibers affected

Glucocorticoid-induced muscle atrophy affects fast-twitch glycolytic muscle fibers (type II muscle fibers). Predominantly IIb fibers are affected, whereas less or no impact is observed on type 1 (oxidative) fibers. [6] The mechanism of such fiber specificity is not known. Type IIb fibers are less frequently active than type IIa or type I fibers, and the differences in normal activity patterns may contribute to the greater steroid-induced atrophy of type IIb fibers. [7]

Mechanism of muscle proteolysis

The catabolic effect of glucocorticoids on muscle proteolysis results from the activation of the major cellular proteolytic systems, [8] namely

  1. The ubiquitin-proteasome system (UPS)
  2. The lysosomal system (cathepsins)
  3. The calcium-dependent system (calpains).
Primarily, myofibrillar proteins are degraded. The ubiquitin-proteasome system is considered to play a major role in the catabolic action of glucocorticoids. [6] The UPS does not degrade the intact myofibrils directly. It is thought that actin and myosin are dissociated probably by calpains, before they can be degraded by the UPS. [9]

Mechanism of inhibition of muscle protein synthesis

There are mechanisms proposed on inhibitory effects of glucocorticoids on protein synthesis.

  1. First, glucocorticoids inhibit the transport of amino acids into the muscle, which could limit the protein synthesis [10]
  2. Secondly, glucocorticoids inhibit the stimulatory action of insulin, insulin-like growth factor-1, and amino acids (leucine in particular) on the phosphorylation of two key factors (4E-BP1 and S6K1). These two factors play a key role in the protein synthesis machinery by controlling the initiation step of mRNA translation [11],[12]
  3. Thirdly, there is evidence that glucocorticoids cause muscle atrophy by inhibiting myogenesis through the down-regulation of myogenin, a transcription factor mandatory for differentiation of satellite cells into muscle fibers. [13]
Other proposed mechanisms for muscle atrophy

  1. Glucocorticoids can also cause muscle atrophy by altering the production of growth factors that control locally the muscle mass development. They inhibit the production of IGF-1 by muscle. IGF-1 stimulates the development of muscle mass by increasing protein synthesis and myogenesis while decreasing proteolysis and apoptosis. Glucocorticoids also stimulate production of myostatin by the muscles. Myostatin inhibits the muscle mass development by down-regulating the proliferation and differentiation of satellite cells and protein synthesis. For these reasons, decreased muscle IGF-1 and increased muscle myostatin play a key role in glucocorticoid-induced muscle atrophy [6]
  2. Another mechanism of glucocorticoid-induced myopathy is mitochondrial dysfunction. The mitochondria are enlarged or aggregated, and their oxidative capacity is decreased due to glucocorticoids action [14]
  3. Glucocorticoids also produce muscle weakness by lowering serum potassium and phosphate. [4]
In cases of Endogenous Cushing's syndrome, elevated levels of ACTH may also be myopathic. Excessive amounts of ACTH can impair neuro-muscular transmission by decreasing the quantal content of the end-plate potential. The ACTH excess, therefore, may have myopathic actions that are separate from those of glucocorticoids. [4]

Hypokalemic myopathy is induced by glucocorticoids with high mineralocorticoid activity. Glucocorticoids produce transient hypophosphatemia due to increased renal clearance of phosphate, and severe phosphate depletion can result in muscle necrosis. However, potassium and phosphate depletion do not play an important role in steroid myopathy. [4]


   Clinical Presentation Top


Cushing first noted that patients with endogenous glucocorticoid excess developed proximal muscle wasting and weakness. [1] Severe muscle weakness is found in 2.4% to 21% of patients with exogenous glucocorticoid administration. [15] Actual incidence of steroid-induced weakness is high if mild cases also included. [15] Some individuals are more predisposed like elderly, patients with cancer, with diseases that affect the respiratory muscles, patients with negative nitrogen balance before the initiation of glucocorticoid treatment, and patients who are physically inactive. [16]

Glucocorticoid-induced myopathy can occur in an acute or chronic form. The acute form most often occurs in the intensive care unit setting. It is characterized by rapidly progressive weakness of the proximal and distal muscle groups. [17] Many of these patients are on mechanical ventilation and have received neuromuscular blockade. Immobility, curare-like agents for neuromuscular blockade, high dose of steroid, nutritional deficiencies, and concurrent sepsis contribute to the rapid onset of weakness and wasting, sometimes referred to acute illness myopathy. [15] In chronic myopathy, muscle weakness develops insidiously, progresses slowly, and is usually painless or mildly painful. [3],[15] Weakness is primarily proximal; pelvic girdle muscles are more severely involved than arms; and cranial nerve innervated muscles and sphincters are spared. Rarely, the distal muscles are affected. [3],[15] Chronic myopathy can lead to muscle atrophy that regresses only after a matter of weeks or months. [17] The pattern of muscle involvement is same in patients with iatrogenic steroid myopathy and endogenous glucocorticoid excess. [15] Patients who have received steroids for less than 4 weeks rarely develop steroid myopathy, although there are wide variations in the dose and duration of steroid treatment associated with glucocorticoid-induced myopathy. [18] The use of prednisone or equivalent drugs in doses of lower than 10 mg/day are rarely associated with glucocorticoid-induced myopathy; higher glucocorticoid doses result in more rapid onset of clinically significant muscle weakness, which can be observed within 2 weeks after the initiation of corticosteroid therapy; the use of prednisone or equivalent drugs in doses of 40-60 mg/day for at least 1 month results in some degree of muscle weakness. [16] Treatment with non-fluorinated glucocorticoids, especially methylprednisolone, has been shown to cause acute muscle weakness in situations of stress, such as acute spinal cord injury or acute respiratory distress syndrome. Inhaled corticosteroids are rarely associated with myopathy; if such myopathy occurs, it can be quickly reversed by interrupting the steroid treatment. [3]


   Diagnostic Evaluation Top


The diagnostic approach to patient with glucocorticoid-induced myopathy involves evaluation for endogenous hypercortisolism or exogenous glucocorticoid use. Serum levels of muscle associated enzymes like creatine kinase, lactate dehydrogenase (LDH), and aldose are usually normal. However, in acute phase, the levels of creatine kinase and aldose may be quite high. [3],[15] On electromyography (EMG), a myopathic pattern is observed in the later stages. EMG results are typically normal in the early stages of the disease. [4] Histologic studies on muscle biopsy reveals non-specific atrophy of type IIb muscle fibers, absence of inflammatory infiltrate, variations in fiber size with centrally placed nuclei, and rarely signs of muscle necrosis. [3]


   Treatment Top


The treatment of underlying etiology for glucocorticoid excess state is important. For exogenous cause, reducing steroid dose, alternate day treatment regimen, and switching to a non-fluorinated agent are associated with improvement in muscle weakness. [15] An increase in muscle strength can be observed within 3 to 4 weeks after discontinuation of the glucocorticoid. An adequate protein intake is helpful in preventing rapid acceleration of symptoms. [15] Physical therapy may be useful in preventing and treating muscle weakness in patients receiving glucocorticoids. [19],[20] Some of the experimental treatments that have been used in glucocorticoid-induced myopathy are IGF-1, branched-chain amino acids, creatine, androgens, and glutamine. [3],[6]

The summary of the review is tabulated in [Table 1].
Table 1: Summary of Glucocorticoid induced myopathy

Click here to view


 
   References Top

1.Cushing H. The basophil adenoma of the pituitary body and their clinical manifestation. Johns Hopkins Med J 1932;50:137.  Back to cited text no. 1
    
2.Stewart PM, Krone NP. The Adrenal Cortex. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, editors. Williams Textbook of Endocrinology. Philadelphia: Elsevier Saunders; 2011. p. 479-544.  Back to cited text no. 2
    
3.Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine 2011;78:41-4.  Back to cited text no. 3
[PUBMED]    
4.Anagnos A, Ruffi RL, Kaminski H. Endocrine myopathies. Neurol Clin 1997;15:673-96.  Back to cited text no. 4
    
5.Dardevet D, Sornet C, Savary I, Debras E, Patureau-Mirand P, Grizard J. Glucocorticoid effects on insulin- and IGF-I-regulated muscle protein metabolism during aging. J Endocrinol 1998;156:83-9.  Back to cited text no. 5
[PUBMED]    
6.Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 2008;197:1-10.  Back to cited text no. 6
[PUBMED]    
7.DuBois DC, Almon RR. Disuse atrophy of skeletal muscle is associated with an increase in number of glucocorticoid receptors. Endocrinology 1980;107:1649-51.  Back to cited text no. 7
[PUBMED]    
8.Hasselgren PO. Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care 1999;2:201-5.  Back to cited text no. 8
[PUBMED]    
9.Hasselgren PO, Fischer JE. Muscle cachexia: Current concepts of intracellular mechanisms and molecular regulation. Ann Surg 2001;233:9-17.  Back to cited text no. 9
[PUBMED]    
10.Kostyo JL, Redmond AF. Role of protein synthesis in the inhibitory action of adrenal steroid hormones on amino acid transport by muscle. Endocrinology 1966;79:531-40.  Back to cited text no. 10
[PUBMED]    
11.Shah OJ, Kimball SR, Jefferson LS. Acute attenuation of translation initiation and protein synthesis by glucocorticoids in skeletal muscle. Am J Physiol Endocrinol Metab 2000;278:E76-82.  Back to cited text no. 11
[PUBMED]    
12.Shah OJ, Kimball SR, Jefferson LS. Among translational effectors, p70S6k is uniquely sensitive to inhibition by glucocorticoids. Biochem J 2000;347:389-97.  Back to cited text no. 12
[PUBMED]    
13.te Pas MF, de Jong PR, Verburg FJ. Glucocorticoid inhibition of C2C12 proliferation rate and differentiation capacity in relation to mRNA levels of the MRF gene family. Mol Biol Rep 2000;27:87-98.  Back to cited text no. 13
[PUBMED]    
14.Mitsui T, Azuma H, Nagasawa M, Iuchi T, Akaike M, Odomi M, et al. Chronic corticosteroid administration causes mitochondrial dysfunction in skeletal muscle. J Neurol 2002;249:1004-9.  Back to cited text no. 14
    
15.Alshekhlee A, Kaminski HJ, Ruff RL. Neuromuscular manifestations of endocrine disorders. Neurol Clin 2002;20:35-58.  Back to cited text no. 15
[PUBMED]    
16.Miller ML. Glucocorticoid-induced myopathy. Up to Date, version 16.3, 2009.  Back to cited text no. 16
    
17.Van Balkom RH, van Der Heijden HF, van Herwaarden CL, Dekhuijzen PN. Corticosteroid induced myopathy of the respiratory muscles. Neth J Med 1994;45:114-22.  Back to cited text no. 17
[PUBMED]    
18.Askari A, Vignos PJ Jr, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med 1976;61:485-92.  Back to cited text no. 18
[PUBMED]    
19.Braith RW, Welsch MA, Mills RM Jr, Keller JW, Pollock ML. Resistance exercise prevents glucocorticoid-induced myopathy in heart transplant recipients. Med Sci Sports Exerc 1998;30:483-9.  Back to cited text no. 19
[PUBMED]    
20.La Pier TK. Glucocorticoid-induced muscle atrophy. The role of exercise in treatment and prevention. J Cardiopulm Rehabil 1997;17:76-84.  Back to cited text no. 20
    



 
 
    Tables

  [Table 1]


This article has been cited by
1 Treatment of pemphigus vulgaris: part 1 – current therapies
Rebecca L. Yanovsky,Michael McLeod,A. Razzaque Ahmed
Expert Review of Clinical Immunology. 2019; : 1
[Pubmed] | [DOI]
2 Omega-3 multiple effects increasing glucocorticoid-induced muscle atrophy: autophagic, AMPK and UPS mechanisms
Alan Fappi,Juliana de C. Neves,Karine A. Kawasaki,Luana Bacelar,Leandro N. Sanches,Felipe P. da Silva,Rubens Larina-Neto,Gerson Chadi,Edmar Zanoteli
Physiological Reports. 2019; 7(1): e13966
[Pubmed] | [DOI]
3 Clinically Relevant Drug-Induced Myopathies
Annie Burke-Doe
Topics in Geriatric Rehabilitation. 2019; 35(1): 72
[Pubmed] | [DOI]
4 Toxicity of glucocorticosteroids in autoimmune blistering diseases
Asli Bilgiç,Dedee F. Murrell
Mucosa. 2019; 2(3): 59
[Pubmed] | [DOI]
5 Skeletal Muscle Response to Deflazacort, Dexamethasone and Methylprednisolone
Panos Fappi,Panos Neves,Panos Sanches,Panos Massaroto e Silva,Panos Sikusawa,Panos Brandão,Panos Chadi,Panos Zanoteli
Cells. 2019; 8(5): 406
[Pubmed] | [DOI]
6 Reduction in stiffness of proximal leg muscles during the first 6 months of glucocorticoid therapy for giant cell arteritis: A pilot study using shear wave elastography
Abdulrahman M. Alfuraih,Ai Lyn Tan,Philip O’Connor,Paul Emery,Sarah Mackie,Richard J. Wakefield
International Journal of Rheumatic Diseases. 2019;
[Pubmed] | [DOI]
7 Clinician’s Commentary on Ospina and McNeely
Krista Johnston
Physiotherapy Canada. 2019; 71(3): 297
[Pubmed] | [DOI]
8 Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis
Chalermrat Bunchorntavakul,K. Rajender Reddy
Alimentary Pharmacology & Therapeutics. 2019;
[Pubmed] | [DOI]
9 Leg muscle strength is reduced and is associated with physical quality of life in Antineutrophil cytoplasmic antibody-associated vasculitis
Arno C. Hessels,Johannes H. van der Hoeven,Jan Stephan F. Sanders,Elisabeth Brouwer,Abraham Rutgers,Coen A. Stegeman,Joanna C. Robson
PLOS ONE. 2019; 14(2): e0211895
[Pubmed] | [DOI]
10 Negative impact of chronic graft-versus-host disease and glucocorticoid on the recovery of physical function after allogeneic hematopoietic stem cell transplantation
Jin Hayakawa,Daijiro Miyamura,Shun-ichi Kimura,Ayumi Gomyo,Masaharu Tamaki,Yu Akahoshi,Naonori Harada,Tomotaka Ugai,Machiko Kusuda,Kazuaki Kameda,Hidenori Wada,Yuko Ishihara,Koji Kawamura,Kana Sakamoto,Miki Sato,Kiriko Terasako-Saito,Misato Kikuchi,Hideki Nakasone,Shinichi Kako,Yoshinobu Kanda
Bone Marrow Transplantation. 2018;
[Pubmed] | [DOI]
11 Increased risk of symptomatic progression of instability following decompression for lumbar canal stenosis in patients receiving chronic glucocorticoids therapy
Shigeto Hiratsuka,Masahiko Takahata,Yoshihiro Hojo,Tomomichi Kajino,Yuichiro Hisada,Akira Iwata,Katsuhisa Yamada,Norimasa Iwasaki
Journal of Orthopaedic Science. 2018;
[Pubmed] | [DOI]
12 Detecting Toxic Myopathies as Medication Side Effect
Elba Gerena-Maldonado
Physical Medicine and Rehabilitation Clinics of North America. 2018;
[Pubmed] | [DOI]
13 Geriatric Assessment of Physical and Cognitive Functioning in a Diverse Cohort of Systemic Lupus Erythematosus Patients: A Pilot Study
Laura Plantinga,Benjamin D. Tift,Charmayne Dunlop-Thomas,S. Sam Lim,C. Barrett Bowling,Cristina Drenkard
Arthritis Care & Research. 2018;
[Pubmed] | [DOI]
14 Glucocorticoid Excess in Bone and Muscle
Amy Y. Sato,Munro Peacock,Teresita Bellido
Clinical Reviews in Bone and Mineral Metabolism. 2018; 16(1): 33
[Pubmed] | [DOI]
15 Cytomegalovirus myositis complicated with hemophagocytic lymphohistiocytosis, acute renal failure, and colitis
Kinya Matsuo,Hideaki Nishihara,Michiaki Koga,Masatoshi Omoto,Junichi Ogasawara,Motoharu Kawai,Takashi Kanda
Rinsho Shinkeigaku. 2018;
[Pubmed] | [DOI]
16 Whole-Body Electromyostimulation Combined With Individualized Nutritional Support Improves Body Composition in Patients With Hematological Malignancies – A Pilot Study
Kristin Schink,Dejan Reljic,Hans J. Herrmann,Julia Meyer,Andreas Mackensen,Markus F. Neurath,Yurdagül Zopf
Frontiers in Physiology. 2018; 9
[Pubmed] | [DOI]
17 Acute steroid myopathy: a highly overlooked entity
M Haran,A Schattner,N Kozak,A Mate,A Berrebi,L Shvidel
QJM: An International Journal of Medicine. 2018;
[Pubmed] | [DOI]
18 Inflammatory myopathy in the context of an unusual overlapping laminopathy
Cristina Guillín-Amarelle,Sofía Sánchez-Iglesias,Antonio Mera,Elena Pintos,Ana Castro-Pais,Leticia Rodríguez-Cañete,Julio Pardo,Felipe F. Casanueva,David Araújo-Vilar
Archives of Endocrinology and Metabolism. 2018;
[Pubmed] | [DOI]
19 Is phrenic nerve conduction affected in patients with difficult-to-treat asthma?
Analúcia Abreu Maranhão,Marcia Maria Jardim Rodrigues,Sonia Regina da Silva Carvalho,Marcelo Ribeiro Caetano,Inaê Mattoso Compagnoni,Tatiana Catia Carnio,Débora Ribeiro
Arquivos de Neuro-Psiquiatria. 2018; 76(3): 177
[Pubmed] | [DOI]
20 Acute myopathy following intra-muscular injection of compound betamethasone
Li-Yuan Sun,Xiao-Ling Chu
Medicine. 2017; 96(34): e7474
[Pubmed] | [DOI]
21 Trajectories of cardiorespiratory fitness in patients with juvenile dermatomyositis
Kiki J. Blom,Tim Takken,Barbara C. H. Huijgen,Judith Wienke,Annet van Royen-Kerkhof,Marco van Brussel
Rheumatology. 2017;
[Pubmed] | [DOI]
22 Resistance and tolerance defenses in cancer: Lessons from infectious diseases
Sheila Rao,Janelle S. Ayres
Seminars in Immunology. 2017;
[Pubmed] | [DOI]
23 Antimalarial myopathy in a systemic lupus erythematosus patient with quadriparesis and seizures: a case-based review
Kashif Jafri,Hengameh Zahed,Katherine D. Wysham,Sarah Patterson,Amber L. Nolan,Matthew D. Bucknor,R. Krishna Chaganti
Clinical Rheumatology. 2017;
[Pubmed] | [DOI]
24 Sexual dimorphism of frailty and cognitive impairment: Potential underlying mechanisms
Qingwei Ruan,Grazia DæOnofrio,Tao Wu,Antonio Greco,Daniele Sancarlo,Zhuowei Yu
Molecular Medicine Reports. 2017; 16(3): 3023
[Pubmed] | [DOI]
25 Minimising fracture risk in older people taking long-term oral corticosteroids
Kerrie Westaway,Oliver Frank,Alan Husband,Anna McClure,Russell Shute,Jane Curtis
Journal of Pharmacy Practice and Research. 2017; 47(2): 158
[Pubmed] | [DOI]
26 Frailty and maximal exercise capacity in adult lung transplant candidates
Aimee M. Layton,Hilary F. Armstrong,Matthew R. Baldwin,Anna J. Podolanczuk,Nicole M. Pieszchata,Jonathan P. Singer,Selim M. Arcasoy,Kimberly S. Meza,Frank DæOvidio,David J. Lederer
Respiratory Medicine. 2017; 131: 70
[Pubmed] | [DOI]
27 Corticosteroids in neurological disorders: The dark side
Dimitrios Parissis,Styliani-Aggeliki Syntila,Panos Ioannidis
Journal of Clinical Neuroscience. 2017;
[Pubmed] | [DOI]
28 Fear and lethality in snowshoe hares: the deadly effects of non-consumptive predation risk
Kirsty J. MacLeod,Charles J. Krebs,Rudy Boonstra,Michael J. Sheriff
Oikos. 2017;
[Pubmed] | [DOI]
29 Simvastatin offers new prospects for the treatment of Duchenne muscular dystrophy
Nicholas P. Whitehead,Min Jeong Kim,Kenneth L. Bible,Marvin E. Adams,Stanley C. Froehner
Rare Diseases. 2016; 4(1): e1156286
[Pubmed] | [DOI]
30 Clinical efficacy maintains patients’ positive attitudes toward fecal microbiota transplantation
Lijuan Xu,Ting Zhang,Bota Cui,Zhi He,Jie Xiang,Chuyan Long,Zhaoyuan Peng,Pan Li,Guangming Huang,Guozhong Ji,Faming Zhang
Medicine. 2016; 95(30): e4055
[Pubmed] | [DOI]
31 Maximizing Function and Quality of Life of Patients with Glioblastoma after Surgical Resection: A Review of Current Literature
Matthew Smith-Cohn,Zhijian Chen,David Peereboom,Glen Stevens
Journal of Cancer Therapy. 2016; 07(12): 857
[Pubmed] | [DOI]
32 Treatment of muscle weakness in neuromuscular disorders
Josef Finsterer,Sinda Zarrouk-Mahjoub
Expert Review of Neurotherapeutics. 2016; : 1
[Pubmed] | [DOI]
33 Orai1 enhances muscle endurance by promoting fatigue-resistant type I fiber content but not through acute store-operated Ca2+ entry
Ellie M. Carrell,Aundrea R. Coppola,Helen J. McBride,Robert T. Dirksen
The FASEB Journal. 2016; 30(12): 4109
[Pubmed] | [DOI]
34 Adrenal fatigue does not exist: a systematic review
Flavio A. Cadegiani,Claudio E. Kater
BMC Endocrine Disorders. 2016; 16(1)
[Pubmed] | [DOI]
35 Physical fitness and physical activity in fatigued and non-fatigued inflammatory bowel disease patients
Lauran Vogelaar,Rita van den Berg-Emons,Hans Bussmann,Robert Rozenberg,Reinier Timman,Christien J. van der Woude
Scandinavian Journal of Gastroenterology. 2015; 50(11): 1357
[Pubmed] | [DOI]
36 Managing Disease and Therapy-Related Complications in Patients with Central Nervous System Tumors
Jeffrey J. Raizer,Karan S. Dixit
Current Treatment Options in Oncology. 2015; 16(8)
[Pubmed] | [DOI]
37 A Framework for Exercise Prescription
Wendy K. Anemaet,Amy Stone Hammerich
Topics in Geriatric Rehabilitation. 2014; 30(2): 79
[Pubmed] | [DOI]
38 Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases
Rita Rastogi Kalyani,Mark Corriere,Luigi Ferrucci
The Lancet Diabetes & Endocrinology. 2014;
[Pubmed] | [DOI]
39 Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease
Sean Robinson Smith,Andrew J. Haig,Daniel R. Couriel
Biology of Blood and Marrow Transplantation. 2014;
[Pubmed] | [DOI]
40 Role of corticosteroids for fatigue in advanced incurable cancer
Sriram Yennurajalingam,Eduardo Bruera
Current Opinion in Supportive and Palliative Care. 2014; 8(4): 346
[Pubmed] | [DOI]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
   Pathophysiology
    Clinical Present...
    Diagnostic Evalu...
   Treatment
    References
    Article Tables

 Article Access Statistics
    Viewed7811    
    Printed69    
    Emailed3    
    PDF Downloaded1283    
    Comments [Add]    
    Cited by others 40    

Recommend this journal